We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+6.92%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$97.5M
AUM Growth
+$12.7M
Cap. Flow
-$2.23M
Cap. Flow %
-2.29%
Top 10 Hldgs %
80.62%
Holding
30
New
10
Increased
6
Reduced
5
Closed
7

Top Buys

1
QLTI
QLT Inc
QLTI
+$5.81M
2
ALR
Alere Inc
ALR
+$3.25M
3
PCRX icon
Pacira BioSciences
PCRX
+$2.56M
4
VCEL icon
Vericel Corp
VCEL
+$2.4M
5
SCMP
Sucampo Pharmaceuticals, Inc.
SCMP
+$2.34M

Top Sells

1
SCLN
Sciclone Pharmaceuticals Inc
SCLN
+$12.7M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$12.2M
3
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$3.38M
4
CTIC
CTI BioPharma Corp. (DE) Common Stock
CTIC
+$1.99M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$1.9M

Sector Composition

1 Healthcare 62.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCLN
1
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
$14.1M 14.5%
1,082,532
-966,106
-47% -$12.7M
VNDA icon
2
Vanda Pharmaceuticals
VNDA
$327M
$9.08M 9.31%
811,563
-1,256,734
-61% -$12.2M
TBRA
3
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$8.01M 8.21%
637,567
-195,410
-23% -$1.82M
FLNA
4
Filana Therapeutics
FLNA
$51.2M
$6.21M 6.37%
405,411
-98,932
-20% -$1.57M
QLTI
5
DELISTED
QLT Inc
QLTI
$5.37M 5.5%
+3,779,274
New +$5.81M
SGNT
6
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$5.34M 5.47%
356,307
+23,242
+7% +$299K
VCEL icon
7
Vericel Corp
VCEL
$2.38B
$5.06M 5.19%
2,250,000
+832,061
+59% +$2.4M
CUTR
8
DELISTED
Cutera, Inc.
CUTR
$4.91M 5.03%
438,000
+65,700
+18% +$721K
SCTL
9
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$3.41M 3.49%
477,967
+213,852
+81% +$1.43M
ALR
10
DELISTED
Alere Inc
ALR
$3.13M 3.2%
+75,000
New +$3.25M
SCMP
11
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$2.35M 2.41%
213,860
+208,632
+3,991% +$2.34M
PCRX icon
12
Pacira BioSciences
PCRX
$1.01B
$1.76M 1.8%
+52,157
New +$2.56M
AVDL
13
DELISTED
Avadel Pharmaceuticals
AVDL
$1.38M 1.41%
+128,005
New +$1.36M
BSTC
14
DELISTED
BioSpecifics Technologies Corp.
BSTC
$1.2M 1.23%
30,000
+4,363
+17% +$160K
DSCI
15
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.12M 1.14%
283,306
-224,493
-44% -$839K
VCYT icon
16
Veracyte
VCYT
$4.72B
$940K 0.96%
+186,926
New +$1M
CPIX icon
17
Cumberland Pharmaceuticals
CPIX
$102M
$580K 0.59%
+128,798
New +$590K
VXRT
18
DELISTED
Vaxart
VXRT
$412K 0.42%
+26,752
New +$445K
DRRX
19
DELISTED
DURECT Corp
DRRX
$98K 0.1%
+8,016
New +$103K
ANIP icon
20
ANI Pharmaceuticals
ANIP
$1.8B
– –
-1,650
Closed -$56K
INSY
21
DELISTED
Insys Therapeutics, Inc.
INSY
– –
-2,000
Closed -$32K
ZLTQ
22
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
– –
-70,000
Closed -$1.9M
PTX
23
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-321,586
Closed -$3.38M
CTIC
24
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
– –
-374,334
Closed -$1.99M
BDSI
25
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-8,523
Closed -$28K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Stonepine Capital Management held 30 positions worth $97.5M, up 15% from $84.8M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Stonepine Capital Management's Q2 2016 filing shows 10 new, 6 increased, 5 reduced and 7 closed positions. Its largest new stake was QLT Inc: 3,779,274 shares worth $5.37M. The largest sale was Sciclone Pharmaceuticals Inc, an estimated $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 92% a quarter earlier.

  • Stonepine Capital Management's largest Q2 2016 buy was QLT Inc: 3,779,274 shares worth $5.37M.
  • Stonepine Capital Management added most to Vericel Corp in Q2 2016, an estimated $2.4M increase.
  • Stonepine Capital Management's biggest Q2 2016 reduction was Sciclone Pharmaceuticals Inc, cutting an estimated $12.7M.
  • Stonepine Capital Management fully exited Pernix Therapeutics Holdings, Inc. in Q2 2016, selling an estimated $3.38M.
  • Stonepine Capital Management's ten largest holdings make up 81% of its $97.5M portfolio in Q2 2016.
  • Stonepine Capital Management opened 10 new positions and closed 7 in Q2 2016.
  • Stonepine Capital Management's portfolio value rose 15% quarter-over-quarter to $97.5M.

Based on Stonepine Capital Management's 13F filing for Q2 2016, filed 10 Aug 2016.